Loading
Life sciences · Journal article
Biochemistry and Biophysics Reports · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Breast cancer remains one of the leading causes of cancer-related mortality in women worldwide, despite significant advances in early detection and conventional therapies. Immunotherapy has emerged as a promising strategy to harness the body's immune system to combat tumors. However, limitations such as immune escape mechanisms and inefficient drug delivery continue to challenge its effectiveness. In recent years, engineered exosomes, cell-derived nanoscale vesicles, have gained attention as innovative carriers for cancer immunotherapy due to their natural biocompatibility, low immunogenicity, and inherent targeting capabilities. This review highlights recent advancements in the design and functionalization of exosomes for breast cancer immunotherapy, including the loading of immune-stimulating molecules, genetic cargos, and surface modifications to enhance tumor specificity. We also discuss their advantages over conventional nanocarriers, immunological mechanisms, preclinical evidence, and challenges related to clinical translation. While significant progress has been made, further research is needed to overcome current barriers and fully exploit the potential of engineered exosomes as a next-generation platform in breast cancer immunotherapy.